Relay Therapeutics, Inc.

Roche’s hopes for recently approved Itovebi to be a key player in the breast cancer space have been advanced by new topline data demonstrating the PI3K inhibitor’s overall survival (OS) benefits. The

Eli Lilly joined the dealmaking fray at the J.P. Morgan Healthcare Conference in San Francisco, announcing on 13 January that it will pay up to $2.5bn for Scorpion Therapeutics to acquire the private

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Zhifei Commits To Acquiring $2.93bn Of

Biopharmaceutical companies celebrated recent positive data readouts with a slew of significant follow-on public offerings (FOPOs), including Nuvalent, Inc. , which grossed $500m on 16 September from